Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on March 27th. The trade occurred in the Representative's "FIDELITY ROTH IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Novo Nordisk A/S NYSE: NVO on 3/27/2025.
• Purchased $50,001 - $100,000 in shares of Amazon.com NASDAQ: AMZN on 2/26/2025.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 2/26/2025.
• Purchased $15,001 - $50,000 in shares of Lockheed Martin NYSE: LMT on 2/18/2025.
• Purchased $1,001 - $15,000 in shares of Lockheed Martin NYSE: LMT on 2/18/2025.
• Sold $1,000,001 - $5,000,000 in shares of The Baldwin Insurance Group NASDAQ: BWIN on 2/7/2025.
• Sold $15,001 - $50,000 in shares of The Baldwin Insurance Group NASDAQ: BWIN on 2/6/2025.
• Sold $50,001 - $100,000 in shares of Costco Wholesale NASDAQ: COST on 1/28/2025.
• Sold $1,001 - $15,000 in shares of Costco Wholesale NASDAQ: COST on 1/28/2025.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $4.89 during midday trading on Thursday, reaching $57.99. 32,159,601 shares of the stock were exchanged, compared to its average volume of 5,952,515. Novo Nordisk A/S has a twelve month low of $57.36 and a twelve month high of $148.15. The company has a market cap of $260.23 billion, a P/E ratio of 17.63, a PEG ratio of 0.90 and a beta of 0.61. The stock's 50 day simple moving average is $76.55 and its 200 day simple moving average is $92.55. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 49.54%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently modified their holdings of NVO. GQG Partners LLC increased its stake in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares during the period. Raymond James Financial Inc. bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $404,910,000. Loomis Sayles & Co. L P increased its stake in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after purchasing an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $158,657,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NVO shares. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $135.00.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.